中药经典名方的研发是促进中医药继承创新和提高临床服务水平的重要途径，经典名方中药材基原的确定对其研发尤为重要，是保证质量、药效及安全性的源头。“术”入药历史悠久，《神农本草经》中列为上品，为经典名方中常用中药。但南北朝以前“苍术”“白术”均可作为“术”入药，未做明确区分，致使本草考证是含“苍术”“白术”经典名方研发中的难题。结合历代本草，从植株形态、产地、性味、功效等方面梳理“术”的历史变迁，以期为“术”的本草考证以及经典名方的研发提供参考借鉴。

The research and development of Chinese materia medica classical prescription is an important way to promote the inheritance and innovation of traditional Chinese medicine and improve the level of clinical services. The determination of the classic Chinese herbal medicine origin is particularly important in its research and development work, and it is the source of ensuring its quality, efficacy and safety. "Zhu" has a long history of medicine, and it is listed as the top grade in Shennong Herbal Classic, which is a commonly used Chinese materia medica in the classic prescription. However, before the Northern and Southern Dynasty, "Atractylodis Macrocephalae Rhizoma" and "Atractylodis Rhizoma" could be used as "zhu" medicines, and no clear distinction was made. As a result, the research on herbal medicine is a difficult problem in the development of the classics containing "Atractylodis Macrocephalae Rhizoma" and "Atractylodis Rhizoma". This study combines the past medicinal herbs, combing the historical changes of "zhu" from the aspects of plant morphology, origin, taste, and efficacy, in order to provide reference for the research and development of the "zhu" and the research and development of the classics.

国家中医药管理局中药标准化项目（ZYBZH-C-JL-25）；国家中医药管理局中药标准化项目（ZYBZH-C-GZ-10）